Health Canada Medical Device License issued for FlowAid’s FA100 SCCD

NEW YORK–(BUSINESS WIRE)– The device treats many circulatory disorders of the lower extremities
and prevents many complications. It introduces a breakthrough in
sequential compression therapies and may be a good alternative to the
standard pneumatic compression therapies, which create external
pressure, and discomfort to the leg. Patients have enhanced quality of
life as they have complete mobility during treatment and can continue
their normal daily schedules.

This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20160822005908/en/

Image may be NSFW.
Clik here to view.

Dr. Jonathan Rosenblum demonstrating the FA100 SCCD for a conference participant. Fay Brezel, Director of Sales, at center. (Photo: Business Wire)

The FlowAid FA100 SCCD is a portable and handheld easy-to-use 4-channel
device that produces a sequence of muscular contractions through four
electrodes placed on the skin of the lower limb. Three user selectable
settings control the frequency of contractions as they pass through
muscle tissue for different treatment protocols. Contractions are distal
to proximal (from the feet to the head) and compress the vasculature in
a peristaltic wave motion forcing the emptying of the deep veins of the
lower limb. Because of increased circulation in the main and peripheral
areas, deoxygenated blood is removed, and oxygen and nutrient rich blood
are delivered to the extremities allowing the natural healing process to
begin.

Medical conditions that can benefit are:

• Peripheral Arterial Disease
• Chronic Venous Inefficiency
• Chronic Ulcers and Wounds such as Diabetic Ulcer
• Lymphedema/Edema
• Prevention of Deep Vein Thrombosis
• Peripheral Neuropathy & Pain
• Other conditions resulting from reduced blood circulation in the
  extremities

Studies and evaluations are currently being conducted in major medical
centers in the UK, Belgium, UAE, Kuwait, India, Austria, and Singapore
with others planned.

Three clinical papers recently published about the product are: (in
title) “…Hypoesthetic Diabetic Foot” in Medical Reports and Case
Studies 2016, (in title) “…Patients with Peripheral
Arterial Disease” in Journal of Novel Physiotherapies 2016, and (in
title) “…Popliteal Venous Blood Flow” in Angiology 2016.
Two more studies have been accepted for publication in Journal of
Vascular Medicine and Surgery and in Journal of Vascular Diagnostics and
Intervention.

FlowAid CEO Jacob Brezel said “We are thrilled to receive the Health
Canada License just four weeks after receiving the European CE
Mark. We are in final preparatory stages for submitting our application
to the FDA for clearance in the United States market.”

FlowAid Medical Technologies Corp. was established in 2015 in New York,
USA. After years of multidisciplinary R&D it has brought its flagship
product to market.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160822005908/en/